{"id":683980,"date":"2026-05-20T23:21:20","date_gmt":"2026-05-20T23:21:20","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/683980\/"},"modified":"2026-05-20T23:21:20","modified_gmt":"2026-05-20T23:21:20","slug":"are-these-rocketing-asx-healthcare-shares-a-must-buy","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/683980\/","title":{"rendered":"Are these rocketing ASX healthcare shares a must buy?"},"content":{"rendered":"

Yesterday the ASX roared back to life<\/a> after a rough few weeks. This included a big gain for three exciting ASX healthcare shares:\u00a0<\/p>\n

These smaller healthcare companies fall within the high risk category of the stock market.\u00a0<\/p>\n

These kinds of shares can deliver outsized returns when clinical trials succeed, regulatory approvals are secured, or breakthrough technologies gain commercial traction.\u00a0<\/p>\n

However, these companies also carry significant risk<\/a> due to limited revenue, funding dependence, and the potential for sharp share price declines if research outcomes or market expectations disappoint.<\/p>\n

Let’s see what was prompting the big gains yesterday and if experts are tipping further upside.\u00a0<\/p>\n

\"Doctor<\/p>\n

Image source: Getty Images<\/p>\n

Tetratherix continues to climb\u00a0<\/p>\n

Tetratherix develops a biostealth fluid matrix for regenerative medicine. The firm offers Tetramatrix as its primary product. <\/p>\n

It has been one of the hottest ASX healthcare stocks in 2026, rising 68% since the start of the year.\u00a0<\/p>\n

The company’s recent quarterly report<\/a> highlighted progress toward commercialising its Tegenix product via a global agreement with Henry Schein and expanding into precision medicine with its STEPP drug-delivery platform, including a lucrative R&D deal.<\/p>\n

This prompted a speculative buy rating from Morgans<\/a> along with an updated price target of $6.84.\u00a0<\/p>\n

From yesterday’s closing price of $5.55, this indicates a further 23% upside.\u00a0<\/p>\n

SDI scheme approved by ASIC<\/p>\n

Yesterday, SDI rose over 7% after a key company announcement.\u00a0<\/p>\n

According to the release, it is being acquired<\/a> by a Chinese-backed buyer group for A$1.40 cash per share through a court-supervised process called a scheme of arrangement.\u00a0<\/p>\n

The Supreme Court of New South Wales has approved SDI holding a shareholder vote and sending shareholders the official Scheme Booklet explaining the deal and including an independent expert’s report.\u00a0<\/p>\n

Shareholders will now review the documents and vote on whether to approve the takeover, which still requires final shareholder and court approval before completion.<\/p>\n

At the time of writing, this ASX healthcare stock is trading for roughly $1.34 per share, meaning the offering is 4.5% higher than the current price.\u00a0<\/p>\n

Saluda Medical shows signs of life\u00a0<\/p>\n

Saluda Medical shares also jumped 7% yesterday.\u00a0<\/p>\n

This was positive news for investors, especially given the stock has fallen more than 65% in 2026.\u00a0<\/p>\n

Saluda Medical is a commercial-stage medical device company commercialising spinal cord stimulation (SCS) therapy. Saluda is currently a single product company, centred around its differentiated SCS product called the ‘Evoke System’.\u00a0<\/p>\n

It looks like this rise could be a sign of what’s to come.\u00a0<\/p>\n

Bell Potter recently placed<\/a> a speculative buy recommendation and $2.00 price target on this ASX healthcare stock.\u00a0<\/p>\n

This implies 300% upside from current levels.\u00a0<\/p>\n

The broker is optimistic thanks to its considerable commercial traction.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Yesterday the ASX roared back to life after a rough few weeks. This included a big gain for…\n","protected":false},"author":2,"featured_media":99264,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-683980","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/683980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=683980"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/683980\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/99264"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=683980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=683980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=683980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}